Thursday, July 8, 2021
HomeHealthcareGSK joins chase for hot cancer target, paying iTeos $625M in new...

GSK joins chase for hot cancer target, paying iTeos $625M in new alliance

GSK concurred to pay $625 million up front to sign up with in the advancement of the drug. Far, iTeos has advanced its TIGIT-targeting drug to early-stage clinical testing in patients with sophisticated strong growths. The Agenus drug is a bispecific antibody. They’ll also share in commercializing the drug– if it’s approved. In the nearer term, the offer instills iTeos with money to support additional cancer drug R&D.

GSK concurred to pay $625 million up front to sign up with in the advancement of the drug. Far, iTeos has actually advanced its TIGIT-targeting drug to early-stage scientific testing in clients with innovative strong growths. In the nearer term, the deal instills iTeos with cash to support extra cancer drug R&D.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments